Hilliard Lyons cut shares of Zoetis (NYSE:ZTS) to a neutral rating in a report released on Thursday, The Fly reports. The analysts noted that the move was a valuation call.
A number of other equities research analysts have also commented on ZTS. Jefferies Group restated a buy rating and set a $96.00 price objective on shares of Zoetis in a report on Friday, April 13th. Citigroup restated a buy rating and set a $98.00 price objective (up from $85.00) on shares of Zoetis in a report on Thursday. ValuEngine upgraded shares of Zoetis from a hold rating to a buy rating in a research note on Monday, April 2nd. Credit Suisse Group lifted their price target on shares of Zoetis from $83.00 to $89.00 and gave the company an outperform rating in a research note on Thursday, April 5th. Finally, BMO Capital Markets reiterated a hold rating on shares of Zoetis in a research note on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. Zoetis currently has an average rating of Buy and a consensus target price of $81.61.
Shares of NYSE:ZTS opened at $85.45 on Thursday. Zoetis has a 12 month low of $54.00 and a 12 month high of $86.38. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. The firm has a market cap of $41,464.95, a P/E ratio of 35.60, a P/E/G ratio of 1.89 and a beta of 0.96.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business posted $0.47 earnings per share. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. research analysts predict that Zoetis will post 3.04 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.59%. Zoetis’s dividend payout ratio is presently 20.83%.
In other news, insider Heidi C. Chen sold 37,453 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total transaction of $3,034,442.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Heidi C. Chen sold 7,383 shares of the business’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $84.71, for a total transaction of $625,413.93. Following the transaction, the insider now owns 20,162 shares in the company, valued at $1,707,923.02. The disclosure for this sale can be found here. Insiders have sold a total of 112,952 shares of company stock worth $9,219,843 over the last 90 days. 0.35% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Zoetis during the 4th quarter worth about $108,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the 3rd quarter worth about $114,000. We Are One Seven LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $120,000. Premia Global Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $122,000. Finally, Icon Wealth Partners LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $127,000. Institutional investors own 92.33% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/23/zoetis-zts-downgraded-to-neutral-at-hilliard-lyons.html.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.